158 related articles for article (PubMed ID: 36518078)
21. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research.
Chen J; Reeves L; Sanburn N; Croop J; Williams DA; Cornetta K
Virology; 2001 Mar; 282(1):186-97. PubMed ID: 11259201
[TBL] [Abstract][Full Text] [Related]
22. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.
Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV
Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Hiraoka K; Kimura T; Logg CR; Tai CK; Haga K; Lawson GW; Kasahara N
Cancer Res; 2007 Jun; 67(11):5345-53. PubMed ID: 17545615
[TBL] [Abstract][Full Text] [Related]
24. Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.
Paar M; Klein D; Salmons B; Günzburg WH; Renner M; Portsmouth D
BMC Mol Biol; 2009 Feb; 10():8. PubMed ID: 19203366
[TBL] [Abstract][Full Text] [Related]
25. Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR.
Allan DS; De Koven A; Wild A; Kamel-Reid S; Dubé ID
Leuk Lymphoma; 1996 Oct; 23(3-4):375-81. PubMed ID: 9031120
[TBL] [Abstract][Full Text] [Related]
26. Improved detection of replication-competent retrovirus.
Forestell SP; Dando JS; Böhnlein E; Rigg RJ
J Virol Methods; 1996 Jul; 60(2):171-8. PubMed ID: 8844623
[TBL] [Abstract][Full Text] [Related]
27. Retroviral vector production.
Miller AD
Curr Protoc Hum Genet; 2014 Jan; 80():12.5.1-12.5.22. PubMed ID: 24510681
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.
Powell SK; Artlip M; Kaloss M; Brazinski S; Lyons R; McGarrity GJ; Otto E
J Virol; 1999 Oct; 73(10):8813-6. PubMed ID: 10482636
[TBL] [Abstract][Full Text] [Related]
29. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors.
Wilson CA; Cichutek K
Methods Mol Biol; 2009; 506():477-88. PubMed ID: 19110646
[TBL] [Abstract][Full Text] [Related]
30. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
[TBL] [Abstract][Full Text] [Related]
31. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
Cornetta K; Duffy L; Turtle CJ; Jensen M; Forman S; Binder-Scholl G; Fry T; Chew A; Maloney DG; June CH
Mol Ther; 2018 Jan; 26(1):280-288. PubMed ID: 28970045
[TBL] [Abstract][Full Text] [Related]
32. Production of high-titer retroviral vectors and detection of replication-competent retroviruses.
Kim YS; Lim HK; Kim KJ
Mol Cells; 1998 Feb; 8(1):36-42. PubMed ID: 9571629
[TBL] [Abstract][Full Text] [Related]
33. [Bio-safety testing for retroviral vector as gene therapy delivery system].
Zhu M; Dai Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Mar; 13(1):48-50. PubMed ID: 12759953
[TBL] [Abstract][Full Text] [Related]
34. Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious.
Ebeling SB; Simonetti ER; Borst HP; Blok A; Schelen AM; Braakman E; Ederveen J; Hagenbeek A
Gene Ther; 2003 Oct; 10(21):1800-6. PubMed ID: 12960969
[TBL] [Abstract][Full Text] [Related]
35. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector.
Hiraoka K; Kimura T; Logg CR; Kasahara N
Clin Cancer Res; 2006 Dec; 12(23):7108-16. PubMed ID: 17145835
[TBL] [Abstract][Full Text] [Related]
36. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein.
Lee ES; Jin SY; Kang BK; Jung YT
J Virol Methods; 2019 Jun; 268():32-36. PubMed ID: 30898575
[TBL] [Abstract][Full Text] [Related]
37. Replication-competent retrovirus vectors for cancer gene therapy.
Tai CK; Kasahara N
Front Biosci; 2008 Jan; 13():3083-95. PubMed ID: 17981778
[TBL] [Abstract][Full Text] [Related]
38. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.
Wang WJ; Tai CK; Kasahara N; Chen TC
Hum Gene Ther; 2003 Jan; 14(2):117-27. PubMed ID: 12614563
[TBL] [Abstract][Full Text] [Related]
39. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Tai CK; Wang WJ; Chen TC; Kasahara N
Mol Ther; 2005 Nov; 12(5):842-51. PubMed ID: 16257382
[TBL] [Abstract][Full Text] [Related]
40. Cell line issues related to specific expression vectors: retrovirus vectors.
Morgan EM
Dev Biol Stand; 1992; 76():301-5. PubMed ID: 1478348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
